{Reference Type}: Journal Article
{Title}: Engineering macrophages and their derivatives: A new hope for antitumor therapy.
{Author}: Wei F;Liu H;Wang Y;Li Y;Han S;
{Journal}: Biomed Pharmacother
{Volume}: 177
{Issue}: 0
{Year}: 2024 Aug 14
{Factor}: 7.419
{DOI}: 10.1016/j.biopha.2024.116925
{Abstract}: Macrophages are central to the immune system and are found in nearly all tissues. Recently, the development of therapies based on macrophages has attracted significant interest. These therapies utilize macrophages' key roles in immunity, their ability to navigate biological barriers, and their tendency to accumulate in tumors. This review explores the advancement of macrophage-based treatments. We discuss the bioengineering of macrophages for improved anti-tumor effects, the use of CAR macrophage therapy for targeting cancer cells, and macrophages as vehicles for therapeutic delivery. Additionally, we examine engineered macrophage products, like extracellular vesicles and membrane-coated nanoparticles, for their potential in precise and less toxic tumor therapy. Challenges in moving these therapies from research to clinical practice are also highlighted. The aim is to succinctly summarize the current status, challenges, and future directions of engineered macrophages in cancer therapy.